Actavis Inc (ACT) 227.31 $ACT
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:55PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) has a notice from Actavis (ACT) regarding the latter's ANDA seeking approval for the generic version of Trokendi XR.
Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Bases Have Different Looks But Share Many Similarities
at Investor's Business Daily - Tue Aug 19, 4:25PM CDT
Investor's Corner has covered the major chart patterns you need to know to find a great stock on the verge of launching a big move up. The cup with handle, double bottom, ascending base and base on base all differ. Yet these and other bases share...
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024
PR Newswire - Tue Aug 19, 10:15AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise® (gabapentin) tablets for the management of postherpetic neuralgia.
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)
PR Newswire - Tue Aug 19, 6:24AM CDT
Actavis plc (NYSE: ACT) today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 2:03PM CDT
Synergy Pharma (SGYP) reported second quarter 2014 loss of 28 cents per share, wider than the year-ago loss of 11 cents and the Zacks Consensus Estimate of a loss of 22 cents.
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna
PR Newswire - Tue Aug 12, 7:40AM CDT
Today, Analysts Review released its research reports regarding Actavis PLC (NYSE: ACT), UnitedHealth Group Inc. (NYS: UNH), Bristol-Myers Squibb Co. (NYSE: BMY), Celgene Corporation (NASDAQ: CELG) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5652-100free.
Leaders Actavis, Salix Trip Sell Signals
at Investor's Business Daily - Fri Aug 08, 5:37PM CDT
The market is now in a correction, so investors need to start playing defense instead of offense. Instead of thinking about what to buy next, look at your portfolio and see what needs to be sold. Leading stocks can correct 1-1/2 to 2-1/2 times the...
Stocks Muted; Keurig Green Mountain Down After Hours
at Investor's Business Daily - Wed Aug 06, 4:07PM CDT
Stocks finished slightly higher Wednesday, recovering from a lower open. Volume ran lighter than the prior day, according to preliminary data. The Nasdaq and the Dow Jones industrial average rose 0.1% and the S&P 500 was up a smidgen. After the...
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Ironwood Pharmaceuticals Narrows Q2 Loss, Revenues Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 10:00AM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share (excluding a one-time write-down of inventory) in the second quarter of 2014.
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Actavis reports 2Q profit
AP - Tue Aug 05, 7:44AM CDT
DUBLIN (AP) — Actavis PLC (ACT) on Tuesday reported a second-quarter profit after posting a loss in the same period a year ago. The company's results beat analysts' expectations.
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
PR Newswire - Tue Aug 05, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 34 percent to $2.67 billion for the second quarter ended June 30, 2014, compared to $1.99 billion in the second quarter 2013. On a non-GAAP basis, diluted earnings per share for the second quarter 2014 increased to $3.42, compared to $2.01 per diluted share in the second quarter 2013. GAAP earnings per diluted share for the second quarter 2014 were $0.28, compared to a GAAP loss per share of $4.27 in the prior year period.
Jim Cramer's Top Stock Picks: ACT AMZN CAH AAPL
at The Street - Tue Aug 05, 5:00AM CDT
Cramer says Actavis is inexpensive and has room to grow while Amazon can begin to rebound soon.
Jim Cramer's 'Mad Money' Recap: Watch Your Back
at The Street - Mon Aug 04, 6:59PM CDT
Forget what the pundits say, the real reason for the market's turmoil remains Russia, Cramer says.
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:55PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) has a notice from Actavis (ACT) regarding the latter's ANDA seeking approval for the generic version of Trokendi XR.
Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Bases Have Different Looks But Share Many Similarities
at Investor's Business Daily - Tue Aug 19, 4:25PM CDT
Investor's Corner has covered the major chart patterns you need to know to find a great stock on the verge of launching a big move up. The cup with handle, double bottom, ascending base and base on base all differ. Yet these and other bases share...
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024
PR Newswire - Tue Aug 19, 10:15AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise® (gabapentin) tablets for the management of postherpetic neuralgia.
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)
PR Newswire - Tue Aug 19, 6:24AM CDT
Actavis plc (NYSE: ACT) today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.
Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 2:03PM CDT
Synergy Pharma (SGYP) reported second quarter 2014 loss of 28 cents per share, wider than the year-ago loss of 11 cents and the Zacks Consensus Estimate of a loss of 22 cents.
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna
PR Newswire - Tue Aug 12, 7:40AM CDT
Today, Analysts Review released its research reports regarding Actavis PLC (NYSE: ACT), UnitedHealth Group Inc. (NYS: UNH), Bristol-Myers Squibb Co. (NYSE: BMY), Celgene Corporation (NASDAQ: CELG) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5652-100free.
Leaders Actavis, Salix Trip Sell Signals
at Investor's Business Daily - Fri Aug 08, 5:37PM CDT
The market is now in a correction, so investors need to start playing defense instead of offense. Instead of thinking about what to buy next, look at your portfolio and see what needs to be sold. Leading stocks can correct 1-1/2 to 2-1/2 times the...
Stocks Muted; Keurig Green Mountain Down After Hours
at Investor's Business Daily - Wed Aug 06, 4:07PM CDT
Stocks finished slightly higher Wednesday, recovering from a lower open. Volume ran lighter than the prior day, according to preliminary data. The Nasdaq and the Dow Jones industrial average rose 0.1% and the S&P 500 was up a smidgen. After the...
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Ironwood Pharmaceuticals Narrows Q2 Loss, Revenues Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 10:00AM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share (excluding a one-time write-down of inventory) in the second quarter of 2014.
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Actavis reports 2Q profit
AP - Tue Aug 05, 7:44AM CDT
DUBLIN (AP) — Actavis PLC (ACT) on Tuesday reported a second-quarter profit after posting a loss in the same period a year ago. The company's results beat analysts' expectations.
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
PR Newswire - Tue Aug 05, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 34 percent to $2.67 billion for the second quarter ended June 30, 2014, compared to $1.99 billion in the second quarter 2013. On a non-GAAP basis, diluted earnings per share for the second quarter 2014 increased to $3.42, compared to $2.01 per diluted share in the second quarter 2013. GAAP earnings per diluted share for the second quarter 2014 were $0.28, compared to a GAAP loss per share of $4.27 in the prior year period.
Jim Cramer's Top Stock Picks: ACT AMZN CAH AAPL
at The Street - Tue Aug 05, 5:00AM CDT
Cramer says Actavis is inexpensive and has room to grow while Amazon can begin to rebound soon.
Jim Cramer's 'Mad Money' Recap: Watch Your Back
at The Street - Mon Aug 04, 6:59PM CDT
Forget what the pundits say, the real reason for the market's turmoil remains Russia, Cramer says.
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.
